Endoscopic ligation of esophageal varices compared with injection sclerotherapy: a prospective randomized trial

Makoto Hashizume, Masayuki Ohta, Kiichiro Ueno, Kazuo Tanoue, Seigo Kitano, Keizo Sugimachi

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Fifty cirrhotic patients with esophageal varices underwent endoscopic treatment in a prospective randomized trial carried out to compare variceal ligation with injection sclerotherapy, with respect to safety, efficacy, and complications in the initial session. Twenty-five patients each were treated using endoscopic variceal ligation or endoscopic injection sclerotherapy in the initial session and then only endoscopic injection sclerotherapy for all following sessions. Ligations numbered 4.1 at the initial session. The total number of sessions of endoscopic injection sclerotherapy was 4.0 ± 1.3 in the endoscopic injection sclerotherapy group compared with 3.6 ± 1.4 in the endoscopic variceal ligation group. The total volume of the sclerosant used by the end of all the sessions was 23.9 ± 10.3 ml in the endoscopic variceal ligation group and 39.0 ± 11.5 ml in the endoscopic injection sclerotherapy group (p < 0.0001). In all patients, complete eradication of the varices was achieved, and at 7 to 15 months follow-up no evidence of recurrence was seen. Adverse effects such as pyrexia, chest pain, and pleural effusion after the initial session were significantly lower in the endoscopic variceal ligation group (p < 0.05), and total bilirubin, serum creatinine, lactate dehydrogenase, and urinary β2-microglobulin were significantly increased and PaO2 decreased after endoscopic injection sclerotherapy (p < 0.05). This study shows that endoscopic variceal ligation significantly decreased the adverse effects associated with endoscopic injection sclerotherapy in the initial session, and it is recommended as an alternative to sclerotherapy.

Original languageEnglish
Pages (from-to)123-126
Number of pages4
JournalGastrointestinal endoscopy
Volume39
Issue number2
DOIs
Publication statusPublished - Jan 1 1993

Fingerprint

Sclerotherapy
Esophageal and Gastric Varices
Ligation
Injections
Sclerosing Solutions
Varicose Veins
Pleural Effusion
Chest Pain
Bilirubin
Creatinine
Fever
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

Endoscopic ligation of esophageal varices compared with injection sclerotherapy : a prospective randomized trial. / Hashizume, Makoto; Ohta, Masayuki; Ueno, Kiichiro; Tanoue, Kazuo; Kitano, Seigo; Sugimachi, Keizo.

In: Gastrointestinal endoscopy, Vol. 39, No. 2, 01.01.1993, p. 123-126.

Research output: Contribution to journalArticle

Hashizume, Makoto ; Ohta, Masayuki ; Ueno, Kiichiro ; Tanoue, Kazuo ; Kitano, Seigo ; Sugimachi, Keizo. / Endoscopic ligation of esophageal varices compared with injection sclerotherapy : a prospective randomized trial. In: Gastrointestinal endoscopy. 1993 ; Vol. 39, No. 2. pp. 123-126.
@article{1126f36e598748e386026b194165b46e,
title = "Endoscopic ligation of esophageal varices compared with injection sclerotherapy: a prospective randomized trial",
abstract = "Fifty cirrhotic patients with esophageal varices underwent endoscopic treatment in a prospective randomized trial carried out to compare variceal ligation with injection sclerotherapy, with respect to safety, efficacy, and complications in the initial session. Twenty-five patients each were treated using endoscopic variceal ligation or endoscopic injection sclerotherapy in the initial session and then only endoscopic injection sclerotherapy for all following sessions. Ligations numbered 4.1 at the initial session. The total number of sessions of endoscopic injection sclerotherapy was 4.0 ± 1.3 in the endoscopic injection sclerotherapy group compared with 3.6 ± 1.4 in the endoscopic variceal ligation group. The total volume of the sclerosant used by the end of all the sessions was 23.9 ± 10.3 ml in the endoscopic variceal ligation group and 39.0 ± 11.5 ml in the endoscopic injection sclerotherapy group (p < 0.0001). In all patients, complete eradication of the varices was achieved, and at 7 to 15 months follow-up no evidence of recurrence was seen. Adverse effects such as pyrexia, chest pain, and pleural effusion after the initial session were significantly lower in the endoscopic variceal ligation group (p < 0.05), and total bilirubin, serum creatinine, lactate dehydrogenase, and urinary β2-microglobulin were significantly increased and PaO2 decreased after endoscopic injection sclerotherapy (p < 0.05). This study shows that endoscopic variceal ligation significantly decreased the adverse effects associated with endoscopic injection sclerotherapy in the initial session, and it is recommended as an alternative to sclerotherapy.",
author = "Makoto Hashizume and Masayuki Ohta and Kiichiro Ueno and Kazuo Tanoue and Seigo Kitano and Keizo Sugimachi",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/S0016-5107(93)70050-4",
language = "English",
volume = "39",
pages = "123--126",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Endoscopic ligation of esophageal varices compared with injection sclerotherapy

T2 - a prospective randomized trial

AU - Hashizume, Makoto

AU - Ohta, Masayuki

AU - Ueno, Kiichiro

AU - Tanoue, Kazuo

AU - Kitano, Seigo

AU - Sugimachi, Keizo

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Fifty cirrhotic patients with esophageal varices underwent endoscopic treatment in a prospective randomized trial carried out to compare variceal ligation with injection sclerotherapy, with respect to safety, efficacy, and complications in the initial session. Twenty-five patients each were treated using endoscopic variceal ligation or endoscopic injection sclerotherapy in the initial session and then only endoscopic injection sclerotherapy for all following sessions. Ligations numbered 4.1 at the initial session. The total number of sessions of endoscopic injection sclerotherapy was 4.0 ± 1.3 in the endoscopic injection sclerotherapy group compared with 3.6 ± 1.4 in the endoscopic variceal ligation group. The total volume of the sclerosant used by the end of all the sessions was 23.9 ± 10.3 ml in the endoscopic variceal ligation group and 39.0 ± 11.5 ml in the endoscopic injection sclerotherapy group (p < 0.0001). In all patients, complete eradication of the varices was achieved, and at 7 to 15 months follow-up no evidence of recurrence was seen. Adverse effects such as pyrexia, chest pain, and pleural effusion after the initial session were significantly lower in the endoscopic variceal ligation group (p < 0.05), and total bilirubin, serum creatinine, lactate dehydrogenase, and urinary β2-microglobulin were significantly increased and PaO2 decreased after endoscopic injection sclerotherapy (p < 0.05). This study shows that endoscopic variceal ligation significantly decreased the adverse effects associated with endoscopic injection sclerotherapy in the initial session, and it is recommended as an alternative to sclerotherapy.

AB - Fifty cirrhotic patients with esophageal varices underwent endoscopic treatment in a prospective randomized trial carried out to compare variceal ligation with injection sclerotherapy, with respect to safety, efficacy, and complications in the initial session. Twenty-five patients each were treated using endoscopic variceal ligation or endoscopic injection sclerotherapy in the initial session and then only endoscopic injection sclerotherapy for all following sessions. Ligations numbered 4.1 at the initial session. The total number of sessions of endoscopic injection sclerotherapy was 4.0 ± 1.3 in the endoscopic injection sclerotherapy group compared with 3.6 ± 1.4 in the endoscopic variceal ligation group. The total volume of the sclerosant used by the end of all the sessions was 23.9 ± 10.3 ml in the endoscopic variceal ligation group and 39.0 ± 11.5 ml in the endoscopic injection sclerotherapy group (p < 0.0001). In all patients, complete eradication of the varices was achieved, and at 7 to 15 months follow-up no evidence of recurrence was seen. Adverse effects such as pyrexia, chest pain, and pleural effusion after the initial session were significantly lower in the endoscopic variceal ligation group (p < 0.05), and total bilirubin, serum creatinine, lactate dehydrogenase, and urinary β2-microglobulin were significantly increased and PaO2 decreased after endoscopic injection sclerotherapy (p < 0.05). This study shows that endoscopic variceal ligation significantly decreased the adverse effects associated with endoscopic injection sclerotherapy in the initial session, and it is recommended as an alternative to sclerotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0027256545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027256545&partnerID=8YFLogxK

U2 - 10.1016/S0016-5107(93)70050-4

DO - 10.1016/S0016-5107(93)70050-4

M3 - Article

C2 - 8495830

AN - SCOPUS:0027256545

VL - 39

SP - 123

EP - 126

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 2

ER -